The neutralization of IL-17A by anti-IL-17A antibodies or supplement of serotonin to block the release of gut Th17 cells might represent a reasonable and feasible therapeutic approaches to improve depression symptoms (92). This evidence concerns the gene IL17A and major depressive disorder.